重症免疫功能低下急性呼吸衰竭患者:单独高流量鼻氧与交替无创通气的随机对照试验
FLORALI-IM为多中心、开放标签、随机对照试验,在29个ICU(法国28个、意大利1个)纳入299例成人免疫功能低下急性呼吸衰竭患者(呼吸频率≥25次/分且PaO2/FiO2≤300 mmHg),1:1随机分为单独HFNO组(154例)与NIV交替HFNO组(145例)。主要终点28天死亡率:单独HFNO组36%(56/154,95%CI 29.2–44.2) vs NIV组35%(51/145,95%CI 27.9–43.2),绝对差1.2%(95%CI -9.6–11.9),p=0.83。除HFNO启动后不适感下降幅度更大(视觉模拟量表-4 mm vs 0 mm,p=0.040)外,其他预设次要终点均无差异。作者认为两组死亡率无差异,但研究把握度有限,结果应谨慎解读。
要点
- 28天死亡率:单独HFNO组36%(56/154,95%CI 29.2–44.2) vs NIV交替HFNO组35%(51/145,95%CI 27.9–43.2),绝对差1.2%(95%CI -9.6–11.9),p=0.83,无统计学差异。
- 除HFNO启动后不适感下降更明显(视觉模拟量表-4 mm[IQR -18至4] vs 0 mm[-16至17],p=0.040)外,其他预设次要终点(ICU/住院/90天/180天死亡率、28天插管、ICU及住院时长、28天无呼吸机天数、28天无氧疗技术天数、疗效与耐受性)均无差异。
- 纳入标准:成人免疫功能低下、急性呼吸衰竭,呼吸频率≥25次/分且PaO2/FiO2≤300 mmHg。
- 关键排除:严重高碳酸血症>50 mmHg、可能强烈受益于NIV者(基础慢性肺病、心源性肺水肿、术后)、严重休克、意识障碍GCS≤12、紧急需要插管、拒绝插管医嘱、NIV禁忌。
- 作者认为两组死亡率无差异,但研究把握度有限,结果应谨慎解读。
适用人群与场景
- 成人免疫功能低下合并急性呼吸衰竭的ICU患者,急性呼吸衰竭定义为呼吸频率≥25次/分且PaO2/FiO2≤300 mmHg。
- 排除:严重高碳酸血症>50 mmHg、可能强烈受益于NIV者(基础慢性肺病、心源性肺水肿、术后)、严重休克、意识障碍GCS≤12、紧急需要插管、拒绝插管医嘱、NIV禁忌。
诊断标准与关键阈值
- 急性呼吸衰竭:呼吸频率≥25次/分且PaO2/FiO2≤300 mmHg。
- 严重高碳酸血症排除阈值:PaCO2>50 mmHg。
- 意识障碍排除阈值:GCS≤12。
处置流程与药物剂量
- 单独HFNO组:持续HFNO,气体流量60 L/min或最高耐受流量。
- NIV组:NIV首次session至少4小时,随后每日session最短12小时,使用专用呼吸机,目标潮气量低于预测体重8 mL/kg,呼气末正压至少8 cm H2O;NIV session间期给予HFNO,HFNO参数同单独HFNO组。
红旗征与不能漏的情况
- 严重高碳酸血症>50 mmHg。
- 严重休克。
- 意识障碍GCS≤12。
- 紧急需要插管。
- 拒绝插管医嘱。
- NIV禁忌。
研究设计与关键结果
- FLORALI-IM为多中心、开放标签、随机对照试验,在29个ICU(法国28个、意大利1个)进行;2017年1月21日至2019年3月4日,497例合格患者中300例随机分组,1例撤回知情同意,299例纳入意向治疗分析(单独HFNO组154例,NIV组145例)。
- 主要终点28天死亡率:单独HFNO组36%(95%CI 29.2–44.2;56/154) vs NIV组35%(95%CI 27.9–43.2;51/145),绝对差1.2%(95%CI -9.6–11.9),p=0.83。
- 除HFNO启动后不适感下降更明显(视觉模拟量表-4 mm[IQR -18至4] vs 0 mm[-16至17],p=0.040)外,其他预设次要终点均无差异。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验(FLORALI-IM,NCT02978300)。
- 局限:作者指出研究把握度有限(study power was limited),结果应谨慎解读。
对床旁实践的改变
- 在重症免疫功能低下急性呼吸衰竭患者中,单独HFNO与NIV交替HFNO的28天死亡率无差异,HFNO启动后不适感下降更明显。
- 作者认为研究把握度有限,结果应谨慎解读。
指南或共识出处
- FLORALI-IM试验,ClinicalTrials.gov注册号NCT02978300,发表于Lancet Respir Med,由法国卫生部资助。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although non-invasive ventilation (NIV) is recommended for immunocompromised patients with acute respiratory failure in the intensive care unit (ICU), it might have deleterious effects in the most severe patients. High-flow nasal oxygen (HFNO) alone might be an alternative method to reduce mortality. We aimed to determine whether HFNO alone could reduce the rate of mortality at day 28 compared with HFNO alternated with NIV.
METHODS: FLORALI-IM is a multicentre, open-label, randomised clinical trial conducted in 29 ICUs (28 in France and one in Italy). Adult immunocompromised patients with acute respiratory failure, defined as respiratory rate of 25 breaths per min or more and a partial pressure of arterial oxygen to inspired fraction of oxygen ratio of 300 mm Hg or lower, were randomly assigned (1:1) to HFNO alone (HFNO alone group) or NIV alternating with HFNO (NIV group). Key exclusion criteria were severe hypercapnia above 50 mm Hg, patients who could strongly benefit from NIV (ie, those with underlying chronic lung disease, with cardiogenic pulmonary oedema, or who were postoperative), severe shock, impaired consciousness defined as Glasgow coma score ≤12, urgent need for intubation, do not intubate order, and contraindication to NIV. Patients were assigned using computer-generated permuted blocks and were stratified according to centre and to the type of immunosuppression using a centralised web-based management system. In the HFNO alone group, patients were continuously treated by HFNO with a gas flow rate of 60 L/min or the highest tolerated. In the NIV group, patients were treated with NIV with a first session of at least 4 h, and then by sessions for a minimal duration of 12 h a day, with a dedicated ventilator, targeting a tidal volume below 8 mL/kg of predicted bodyweight, and with a positive end-expiratory level of at least 8 cm H2O. NIV sessions were interspaced with HFNO delivered as in the HFNO alone group. The primary outcome was mortality at day 28 and was assessed in the intention-to-treat population. Secondary outcomes were mortality in the ICU, in hospital, at day 90 and at day 180, intubation at day 28, length of stay in the ICU and in hospital, number of ventilator-free days at day 28, number of oxygenation technique-free days at day 28, and efficacy and tolerance of oxygenation techniques. The trial is registered with ClinicalTrials.gov, NCT02978300, and is complete.
FINDINGS: Between Jan 21, 2017 to March 4, 2019, of 497 eligible patients, 300 were randomly assigned but one patient withdrew consent, leaving 299 patients included in the intention-to-treat analysis (154 assigned to the HFNO alone group and 145 assigned to NIV group). Mortality rate at day 28 was 36% (95% CI 29·2 to 44·2; 56 of 154 patients) in the HFNO alone group and 35% (27·9 to 43·2; 51 of 145 patients) in the NIV group (absolute difference 1·2% [95% CI -9·6 to 11·9]; p=0·83). None of the other prespecified secondary outcomes were different between groups except for greater decreased discomfort after initiation of HFNO than with NIV (-4 mm on visual analogic scale [IQR -18 to 4] vs 0 mm [-16 to 17]; p=0·040).
INTERPRETATION: In critically ill immunocompromised patients with acute respiratory failure, the mortality rate did not differ between HFNO alone and NIV alternating with HFNO. However, study power was limited, so results should be interpreted with caution.
FUNDING: French Ministry of Health.
参考来源
- Coudroy R, Frat JP, Ehrmann S, et al. High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial. Lancet Respir Med. 2022. PMID: 35325620. doi:10.1016/S2213-2600(22)00096-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。